Characteristics and clinical significance of oxidized lipid metabolites in cerebrospinal fluid in patients with closed craniocerebral injury

doi:10.3877/cma.j.issn.2095-123X.2019.04.003

Abstract

Abstract:

Objective

To explore the characteristics and clinical significance of oxidized lipid metabolites in cerebrospinal fluid in patients with closed craniocerebral injury.

Methods

During the period of January 2018 to December 2018, according to GCS score, 60 patients with closed craniocerebral injury were divided into light group (GCS 13-15 score), medium group (GCS 8-12 score) and heavy group (GCS 3-7 score), 20 cases in each group, and randomly selected 20 cases of health adult as normal group. All cerebrospinal fluid samples were detected by chromatography-electrospray mass spectrometry, and the clinical prognosis of all patients was evaluated by National Institute of Health stroke scale (NIHSS) score at the 6^th month after treatment, and the difference characteristics of oxidized lipid metabolites in each group of cerebrospinal fluid samples and their correlation with NIHSS score were calculated and analyzed.

Results

Three levels of increased metabolites and five levels of decreased metabolites (FC≥1, P<0.05) were detected in patients with closed craniocerebral injury. The level of increased oxidative lipid metabolites were LTB4, 5-oxoETE and 15-oxoETE, and the level of decreased oxidative lipid metabolites were PGJ2, LXA4, PGF3, TXB3 and RVD5. Among them, only 15-oxoETE was dependent on the severity of the disease (P<0.05). There was a significant positive correlation between 15-oxoETE and NIHSS (P<0.05).

Conclusion

The level of oxidized lipid metabolites in cerebrospinal fluid of patients with closed craniocerebral injury has a significant change, and the significantly increased level of 15-oxoETE has a predictive effect on the poor clinical prognosis.

Key words: Craniocerebral injury, Oxidized lipid metabolism, Lipid mediator

Chuanghuan Zou, Fa Jin, Dingchao Long. Characteristics and clinical significance of oxidized lipid metabolites in cerebrospinal fluid in patients with closed craniocerebral injury[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2019, 09(04): 201-204.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2019.04.003

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2019/V09/I04/201

Figures/Tables 3

References 21

[1]	Garreta-Lara E,Checa A,Fuchs D, et al. Effect of psychiatric drugs on daphnia magna oxylipin profiles[J]. Sci Total Environ, 2018, 644: 1101-1109.
[2]	Moolenaar WH,Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator[J]. Nat Rev Mol Cell Biol, 2011, 12(10): 674-679.
[3]	Cartier A,Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy[J]. Science, 2019, 366(6463): 5551.
[4]	Michos ED,McEvoy JW,Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease[J]. N Engl J Med, 2019, 381(16): 1557-1567.
[5]	Backes JM,Ruisinger JF,Gibson CA, et al. Statin-associated muscle symptoms-managing the highly intolerant[J]. J Clin Lipidol, 2017, 11(1): 24-33.
[6]	Quispe R,Hendrani A,Elshazly MB, et al. Accuracy of low-density lipoprotein cholesterol estimation at very low levels[J]. BMC Med, 2017, 15(1): 83.
[7]	Martin SS,Blaha MJ,Elshazly MB, et al. Comparison of a novel method vs the friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile[J]. JAMA, 2013, 310(19): 2061-2068.
[8]	Sathiyakumar V,Park J,Golozar A, et al. Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy[J]. Circulation, 2018, 137(1): 10-19.
[9]	US Preventive Services Task Force, Bibbins-Domingo K,Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement[J]. JAMA, 2016, 316(19): 1997-2007.
[10]	刘海英,江涛.高压氧干预对颅脑损伤患者脑氧代谢、脑损伤及氧化应激反应的影响[J].海南医学院学报, 2018, 24(18): 1661-1665.
[11]	Rodríguez-Rodríguez A,Egea-Guerrero JJ,Murillo-Cabezas F, et al. Oxidative stress in traumatic brain injury[J]. Curr Med Chem, 2014, 21(10): 1201-1211.
[12]	王玖红.脑脊液生化指标对中枢神经系统性疾病患者病情严重程度的评估价值[J].检验医学与临床, 2019, 16(20): 3043-3045.
[13]	Rahimi J,Woehrer A. Overview of cerebrospinal fluid cytology[J]. Handb Clin Neurol, 2017, 145: 563-571.
[14]	Surmiak M,Gielicz A,Stojkov D, et al. LTB4 and 5-oxo-ETE from extracellular vesicles stimulate neutrophils in granulomatosis with polyangiitis[J]. J Lipid Res, 2019, Epub ahead of print.
[15]	Loell I,Alemo Munters L,Pandya J, et al. Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis[J]. Ann Rheum Dis, 2013, 72(2): 293-299.
[16]	Bhatt L,Roinestad K,Van T, et al. Recent advances in clinical development of leukotriene B4 pathway drugs[J]. Semin Immunol, 2017, 33(11): 65-73.
[17]	Snyder NW,Golin-Bisello F,Gao Y, et al. 15-oxoeicosatetraenoic acid is a 15-hydroxyprostaglandin dehydrogenase-derived electrophilic mediator of inflammatory signaling pathways[J]. Chem Biol Interact, 2015, 234(5): 144-153.
[18]	Abbasi S,Kajimoto K,Harashima H. Elimination of the biphasic pharmacodynamics of 15d-PGJ2 by controlling its release from a nanoemulsion[J]. Int J Nanomedicine, 2016, 11(8): 2685-2694.
[19]	Luo YY,Wu SH,Lu HY, et al. Lipoxin A4 attenuates hyperoxia-induced lung epithelial cell injury via the upregulation of heme oxygenase-1 and inhibition of proinflammatory cytokines[J]. Mol Med Rep, 2019, Epub ahead of print.
[20]	Ke Y,Zebda N,Oskolkova O, et al. Anti-inflammatory effects of OxPAPC involve endothelial cell-mediated generation of LXA4[J]. Circ Res, 2017, 121(3): 244-257.
[21]	Luo X,Gu Y,Tao X, et al. Resolvin D5 inhibits neuropathic and inflammatory pain in male but not female mice: distinct actions of d-series resolvins in chemotherapy-induced peripheral neuropathy[J]. Front Pharmacol, 2019, 10: 745.

组别	例数	性别（男/女）	年龄（岁，Mean±SD）
轻型组	20	12/8	39.15±15.23
中型组	20	9/11	39.70±10.78
重型组	20	13/7	39.65±15.09
对照组	20	10/10	40.80±12.82
χ²/F值	?	2.020	0.052
P值	?	0.568	0.984

组别	例数	性别（男/女）	年龄（岁，Mean±SD）
轻型组	20	12/8	39.15±15.23
中型组	20	9/11	39.70±10.78
重型组	20	13/7	39.65±15.09
对照组	20	10/10	40.80±12.82
χ²/F值	?	2.020	0.052
P值	?	0.568	0.984

Please choose a citation manager

Content to export